WAYNE, Pa.--(BUSINESS WIRE)--Jun. 20, 2018--
Teleflex Incorporated (NYSE: TFX) will present at the World Congress on
Vascular Access 2018 in Copenhagen, Denmark from June 20th to
June 22nd. Teleflex’s theme will be Right Line, Right
Patient, Right Time™. Teleflex will feature Arrowg+ard Blue Advance™
Peripherally Inserted Central Catheters (PICC). In addition, Teleflex
will showcase the Arrow® VPS Rhythm™ Device.
The Arrow® VPS Rhythm™ Device provides ECG-based tip
confirmation in a highly portable, lightweight and versatile design (the
system can be used in combination with every type of central venous
access). The Arrow® VPS Rhythm™ Device with ECG Technology
assists in placement and confirmation of the catheter tip in the SVC-CAJ
(superior vena cava-cavoatrial junction), and may be used with a broad
range of catheter types.
When paired with the TipTracker™ Stylet, the Arrow® VPS
Rhythm™ Device with TipTracker™ Technology provides real-time catheter
navigation of a PICC and ECG-based tip positioning, with a visual blue
line that tracks along the catheter pathway.
Arrowg+ard Blue Advance™ Protection (formerly branded as Arrow®
Chlorag+ard Technology) is the 3rd generation of chlorhexidine-based
protective treatment from Teleflex. Teleflex recently announced the
rebranding of all Arrow® Chlorag+ard Technology products,
which will going forward be known as Arrowg+ard Blue Advance™ Products.
This change affects all PICC, JACC, and Midline products with Arrow®
Chlorag+ard Technology. Although the brand name is changing, there is no
change to the design, specifications, manufacturing process, intended
use, product number or packaging of these products. As shown in in vivo
and in vitro studies, Arrowg+ard Blue Advance™ Protection provides
protection against thrombus accumulation on the catheter surface (92%
reduction in fibrin sheath formation on catheter surfaces in an in vivo
ovine model when challenged with staphylococcus aureus),1
reduced intraluminal thrombotic occlusion3 and protection
against bacterial colonization (99.99% catheter colonization reduction
in Gram positive and Gram bacteria, and fungal pathogens in an in vitro
study)2. Arrowg+ard Blue Advance™ Catheters provide
protection for at least 30 days.
These innovative products join our market-leading products, Arrowg+ard
Blue™CVCs, antimicrobial treated central venous catheters,
and the Arrow® EZ-IO® Intraosseous Access System
enabling clinicians to expand their options when choosing the Right Line
for the Right Patient at the Right Time.
Participants in the Congress will have the opportunity to be introduced
to Teleflex Academy, an innovative clinical education platform
incorporating interactive online learning, live courses and other
educational offerings. In-booth educational programs at the Congress
will focus on aspects of vascular access designed to inspire confidence,
enhance skills and enable clinicians to make an even bigger difference
in patient’s lives. Teleflex believes that quality clinical education is
the first step in fostering the expansion of skills to shape clinical
practice.
Throughout the Congress, Teleflex will host several educational sessions
presented by their clinical team. These presentations will take place
from Wednesday 20th through Friday 22nd June.
Presentations include – “Device selection: Right Line Right Vein”; “Use
of the Arrow® EZ-IO® System in the Pre-Arrest
Patient” and “Clinical Benefits of Intracavitary ECG & Navigation”.
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to
improve the health and quality of people’s lives. We apply purpose
driven innovation – a relentless pursuit of identifying unmet clinical
needs – to benefit patients and healthcare providers. Our portfolio is
diverse, with solutions in the fields of vascular and interventional
access, surgical, anesthesia, cardiac care, urology, emergency medicine
and respiratory care. Teleflex employees worldwide are united in the
understanding that what we do every day makes a difference. For more
information, please visit teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson
RCI®, LMA®, Pilling®, Rüsch®
and Weck® – trusted brands united by a common sense of
purpose.
Forward-Looking Statements
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements. Any
forward-looking statements contained herein are based on our
management's current beliefs and expectations, but are subject to a
number of risks, uncertainties and changes in circumstances, which may
cause actual results or company actions to differ materially from what
is expressed or implied by these statements. These risks and
uncertainties are identified and described in more detail in our filings
with the Securities and Exchange Commission, including our Annual Report
on Form 10-K.
Teleflex, the Teleflex logo, Arrow, Arrowg+ard, Arrowg+ard Blue,
Arrowg+ard Blue Advance, Deknatel, EZ-IO, Hudson RCI, LMA, Pilling,
Right Line, Right Patient, Right Time, Rüsch, TipTracker, VPS Rhythm and
Weck are trademarks or registered trademarks of Teleflex Incorporated or
its affiliates, in the U.S. and/or other countries. © 2018 Teleflex
Incorporated. All rights reserved.
VA-BC is a trademark of the Vascular Access Certification Corporation.
References:
1. As compared to uncoated PICCs, intravascular
ovine model inoculated with Staph aureus. No correlation between in
vitro / in vivo testing methods and clinical outcomes have currently
been ascertained.
2. In vitro data on file 2010. No correlation
between in vitro / in vivo testing methods and clinical outcomes have
currently been ascertained.
3. As compared to uncoated PICCs, in
vitro model measuring flush pressure post exposure to human blood. No
correlation between in vitro / in vivo testing methods and clinical
outcomes have currently been ascertained.
4. As compared to
uncoated PICCs, intravascular ovine model. No correlation between in
vitro / in vivo testing methods and clinical outcomes have currently
been ascertained.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180620005663/en/
Source: Teleflex Incorporated
Teleflex Incorporated
Jake Elguicze
Treasurer and Vice
President, Investor Relations
610-948-2836
or
Emmet Dalton
Director
Marketing Communications International
+353 873333262
emmet.dalton@teleflex.com